ATRX Mutations Reshape Chromatin Architecture to Drive Glioma Progression, Exposing HOXA as a Therapeutic Target
核心洞察
Researchers at MD Anderson Cancer Center discovered that ATRX (搜索) mutations reprogram the 3D chromatin structure in glioma (搜索) cells, creating new DNA interactions that activate developmental pathways driving tumor growth.
The study identified WNT5A (搜索), SLITRK6 (搜索), and multiple HOXA (搜索) genes as key pathways activated by ATRX (搜索) deficiency, with HOXA signaling emerging as a particularly promising therapeutic vulnerability.
Blocking HOXA (搜索)-mediated signaling with the peptide HXR9 led to cancer cell death, slowed tumor growth, and extended survival in preclinical in vivo models.
A new study from The University of Texas MD Anderson Cancer Center has revealed how one of the most common genetic alterations in glioma (搜索) fundamentally rewires the cancer cell genome to fuel tumor progression, uncovering a potential new therapeutic strategy for patients with ATRX (搜索)-mutant gliomas. The findings, published in Nucleic Acids Research, demonstrate that mutations in the ATRX gene reprogram the epigenome and alter the three-dimensional structure of chromatin, creating new interactions that activate developmental programs which tumors exploit to grow and spread.
The study was co-led by Jason Huse, M.D., Ph.D., professor of Anatomic Pathology, and Kunal Rai, Ph.D., professor of Genomic Medicine, with major contributions from Prit Benny Malgulwar, Ph.D., instructor of Translational Molecular Pathology, Anand Singh, Ph.D., senior research scientist in Genomic Medicine, and Ajay Saw, Ph.D., previous postdoctoral fellow in Genomic Medicine.
"ATRX (搜索) mutations are a defining feature in many gliomas. Our findings show that losing ATRX doesn't just cause random damage but actually reprograms gene regulation architecture in ways that drive glioma (搜索) formation and progression," Huse said. "The next generation of personalized medicine will depend on integrating these genetic, epigenetic and structural components in order to identify the right treatment for the right patient at the right time."
The Role of ATRX in Brain Cancer
The ATRX (搜索) protein helps organize and regulate DNA. Mutations that inactivate ATRX disrupt DNA repair and allow cancer cells to multiply uncontrollably. ATRX mutations are a defining feature in several cancers, including gliomas. While researchers have known these mutations are somehow involved in cancer development, it was not clearly understood how they influence cell behavior.
The researchers found that ATRX (搜索)-deficient cells change DNA folding patterns and create new interactions in chromatin — the tightly packed complex of DNA, RNA and proteins that form chromosomes. This reorganization of chromatin structure leads to the activation of new gene pathways that promote tumor progression.
Key Pathways Activated by ATRX Deficiency
The study identified several critical pathways activated downstream of ATRX (搜索) loss. These include WNT5A (搜索), which is linked to cancer cell movement and neurogenesis; SLITRK6 (搜索), which is linked to cell migration and malignant brain tumors; and multiple HOXA (搜索) genes that control spatial and temporal patterns in early brain development.
Preclinical Evidence for Targeting HOXA Signaling
The researchers demonstrated that blocking WNT5A (搜索) or SLITRK6 (搜索) slowed cancer cell movement in vitro. More significantly, targeting HOXA (搜索) genes blocked tumor progression. The team tested a peptide called HXR9 to disrupt HOXA-mediated signaling, which led to cancer cell death, slowed tumor growth, and extended survival in vivo.
"This study underscores the need to examine the functional consequences of genetic mutations rather than solely focusing on the mutations themselves," Rai said. "These findings could also apply to ATRX (搜索) mutations in other cancers and, on a larger level, epigenetic dysfunction reprogramming cellular differentiation state and plasticity."
Clinical Implications and Future Directions
Further clinical research is needed, but these results suggest that targeting the HOXA (搜索) pathway could be a promising strategy for treating ATRX (搜索)-deficient brain tumors and other ATRX-mutant cancer types. Current treatment options for many gliomas remain limited, and these new biomarkers and potential drug targets could help researchers and clinicians develop more precise therapies that can address ATRX deficiency.